Atai Life Sciences N.V. (ATAI )

Currency in USD Disclaimer
$2.25 +$0.4 (21.62%)
Closed 02/04/2025
$1.78
$2.32
$1.03
$2.85

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol ATAI
  • Company Atai Life Sciences N.V.
  • Price $2.25
  • Changes Percentage 21.62
  • Change 0.4
  • Day Low $1.78
  • Day High $2.32
  • Year High $2.85
  • Year Low $1.03
  • Market Cap $377,554,500
  • Price Avg 50 EMA (D) $1.5
  • Price Avg 200 EMA (D) $1.44
  • Exchange NASDAQ
  • Volume 12,635,823
  • Average Volume 1,919,561
  • Open $1.86
  • Previous Close $1.85
  • EPS -0.8
  • PE -2.81
  • Earnings Announcement 2025-03-26 12:30:00
  • Shares Outstanding $167,802,000

Company brief: ATAI LIFE SCIENCES N.V. (ATAI )

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

ATAI Corporation News

atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout

atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout

February 3, 2025 at 6:30 pm ET

proactiveinvestors.com -- Positive data from Irish biotechnology firm GH Research's Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT), in treatment-resistant depression bodes well for atai ...

Income Statement